Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

With vasa-Cas9, high efficiency and self-limiting suppression was achieved. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.